CD38 in Basic Science: Reflecting on the Past to Move to the Future
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 276
Special Issue Editors
Interests: acute lymphoblastic leukemia; acute myeloid leukemia; myelodysplastic syndromes; multiple myeloma and MGUS; non-Hodgkin and Hodgkin lymphoma
Special Issues, Collections and Topics in MDPI journals
Interests: antibody therapy; human myeloma; leukemia; IgG receptors; immune modulation
Special Issues, Collections and Topics in MDPI journals
2. Division of Hematology & Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
Interests: multiple myeloma; MGUS; chronic lymphocytic leukemia; waldenstrom macroglobulinemia; immunotherapy; cancer vaccines; antibody therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
More than three decades of research on CD38 and its role in human diseases has culminated in the recent development of agents that target CD38 for clinical applications. The formal approval and expanding use of anti-CD38 therapeutic antibodies have allowed them to become an important treatment option in the management of multiple myeloma. On the heels of this success, the efficacy of CD38-targeting agents is being actively investigated for patients with other hematologic malignancies, solid tumour cancers, and autoimmune disorders, as well as pathologies related to ageing, neurodegenerative disorders, neuropsychology, and cardiovascular disease.
With an abundance of scientific data being released on CD38 biology and the development of novel anti-CD38 therapies, our conference entitled, “CD38 in Basic Science and Clinical Practice: Reflecting on the Past to Move into the Future” is timely, and will bring together experts investigating the role of CD38 in cancer, ageing, autoimmunity, neurology and behaviour. This important conference will foster much needed engagement between clinicians, basic-science researchers and pharmaceutical companies working on CD38. As anti-CD38 therapies are currently approved for use in patients with multiple myeloma, a major theme of the meeting will be on the optimal use of these agents and novel therapeutic strategies once patients stop responding to the targeted interference of CD38. The meeting is being organized by experts in the field (Drs. Cerchione, Paulus, and Malavasi) with the support of their respective academic institutes and patronage from various professional societies, pharmaceutical partners, and philanthropists.
This Special Issue aims to collect papers related to major topics of our conference, including Reviews, Original papers, Commentaries and Editorials.
Dr. Claudio Cerchione
Prof. Dr. Fabio Malavasi
Dr. Aneel Paulus
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CD38
- multiple myeloma
- myeloma
- MGUS
- monoclonal antibodies
- immunotherapy
